Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Biopharmaceutical industry remains mixed over EU reform proposals, finds GlobalData

Reforms to the European Union’s (EU) general pharmaceutical legislation emerge as one of the key policy developments affecting the operating environment for the pharma industry. In a survey, respondents’ opinions on the impact of EU reform proposals were mixed, with the percentage of participants expressing positive, negative, or neutral views remaining varied, according to GlobalData, […]
Read more

IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space, says GlobalData

At this year’s European Renal Association, positive results were presented from Human Immunology Bioscience’s (HI-Bio) interim results of the Phase II IGNAZ clinical trial. According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN). The drug potentially fills an unmet […]
Read more

Neurology remains key therapeutic area for Japan pharma majors, says GlobalData

In the dynamic landscape of healthcare, key neurological disorders like Alzheimer’s disease, epilepsy, Parkinson’s disease, and depression pose significant challenges, particularly in the Asia-Pacific (APAC) region, where prevalence is high. The World Health Organization stated in March 2024 that “over 80% of neurological deaths and health losses occur in low- and middle-income countries, and access […]
Read more

Verona’s Ensifentrine attracts positive opinions in light of anticipated US launch for COPD, says GlobalData

Verona Pharma recently announced that they are finalizing preparations for a potential US launch of Ensifentrine in the third quarter of 2024, depending upon the FDA’s approval, set for June 26, 2024. The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor aims to reduce exacerbations in chronic obstructive pulmonary disease (COPD) patients, administered as a nebulized formulation. […]
Read more

Osteoporosis Awareness & Prevention Month highlights need for prioritizing early diagnosis and advanced treatments, says GlobalData

The Bone Health and Osteoporosis Foundation (BHOF) observes the month of May every year as Osteoporosis Awareness & Prevention Month to shed light on the critical needs of those living with osteoporosis. Advocates emphasize the importance of enhancing education, research, and healthcare strategies to tackle this prevalent, yet frequently neglected condition. Prioritizing prevention, early diagnosis, […]
Read more

Innovent Biologics mazdutide can pave way for transformative T2D treatment, says GlobalData

Innovent Biologics Inc has recently unveiled promising Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. With its potential to revolutionize T2D treatment, mazdutide’s success could not only reshape the landscape of diabetes therapeutics in China but also underscores the growing demand for […]
Read more

Non-injectable medication development remains significant unmet need in female infertility, says GlobalData

Great progress has been made in the management of female infertility since the introduction of assisted reproductive technology, predominantly in vitro fertilization (IVF). However, despite the improvements made in the space, challenges associated with the treatment remain. The development of non-injectable fertility medications represents a significant unmet need, according to key opinion leaders (KOLs) interviewed […]
Read more

World AIDS Vaccine Day 2024: Prophylactic vaccines in phase II development hold potential to reduce epidemic burden, says GlobalData

World AIDS (acquired immunodeficiency syndrome) Vaccine Day, also known as HIV (human immunodeficiency virus) Vaccine Awareness Day, takes place annually on 18 May. The National Institute of Allergy and Infectious Diseases (NIAID) leads the observance, educating the public on the importance of HIV prevention and the significance of vaccine research, and acknowledging the contributions of […]
Read more

Roche challenges Regeneron and Bayer’s position as industry leaders within wAMD, DME and DR spaces, says GlobalData

Roche’s Vabysmo (faricimab) is in the spotlight following its promising Q1 2024 sales figures. Vabysmo, a vascular endothelial growth factor (VEGF) inibitior and angiopoietin-2 (Ang-2) inhibitor therapy, is indicated for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). This presents a looming challenge to Regeneron and […]
Read more

Anticipation builds as Insmed bronchiectasis therapy brensocatib nears Phase III completion, observes GlobalData

Insmed is in the spotlight over the past few years for its pipeline agent, brensocatib, which has previously shown promising Phase II results, generating anticipation within the medical community ahead of their Phase III results for the treatment of bronchiectasis. The positive outcomes could pave the way for regulatory approval, potentially transforming the therapeutic landscape […]
Read more
1 … 20 21 22 23 24 … 110